On August 21st, Gelonghui (688273.SH) released its semi-annual report. In the first half of 2024, the company achieved operating revenue of 228.3842 million yuan, an increase of 11.73% year-on-year. The net profit attributable to shareholders of the listed company was 72.6067 million yuan, an increase of 23.39% year-on-year. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 66.059 million yuan, an increase of 32.81% year-on-year. Cash dividends of 4.00 yuan per 10 shares were distributed to all shareholders.
The company insists on technological innovation in order to create the number one brand in obstetric rehabilitation. At the same time, the company has been recognized by the Ministry of Industry and Information Technology as a manufacturing industry champion. During the reporting period, the company's R&D investment was 26.4179 million yuan, a decrease of 2.3886 million yuan compared to the previous year, a year-on-year decrease of 8.29%, accounting for 11.57% of the revenue. The total number of R&D personnel at the end of the period was 153, an increase of 19.53% year-on-year. The company continues to increase R&D investment and promote the transformation of achievements. During the reporting period, it submitted 14 patent and software copyright applications, including 4 invention patents. 15 new patents and software copyright were granted, including 8 authorized invention patents, and core intellectual property achievements were significant. Currently, the company has formed five major technology platforms: sound, light, electricity, heat, and magnetic. At the same time, it continues to integrate artificial intelligence technology and has completed the "Pelvic Floor Intelligent Diagnosis and Treatment System (PI-ONE System)" series of new products, which will be fully launched in the market in March 2024.
